July 27, 2022 — Viz.ai, a leading AI-powered disease detection and intelligent care coordination platform, announced it is partnering with Hyperfine, Inc., creator of the first FDA-cleared point-of-care magnetic resonance imaging (MRI) device, Swoop. Together, they will bring MRI to the patient’s bedside and deliver valuable insights to the clinician’s fingertips for timely decision making.
The mission of Viz.ai is to fundamentally improve how healthcare is delivered in the world through intelligent software that promises to reduce time to treatment, improve access to care, and increase the speed of medical innovation. Viz.ai’s flagship product, Viz LVO, leverages advanced deep learning to communicate time-sensitive information about stroke patients straight to a specialist who can intervene and treat. In stroke, speed matters, as delays in care can lead to severe morbidity and mortality.
Swoop, the world’s first MR imaging system capable of providing neuroimaging at the point of care, expands patient access to MRI by bringing imaging to the bedside. The Swoop system allows physicians to make quick and informed clinical decisions for patients, eliminating hours of wait and transport time and reducing the potential for adverse events associated with transporting critically ill patients.
This partnership and subsequent implementation in neuro ICUs provide the potential to further decrease the time from admission to treatment by expediting clinician access to MRI imaging and increasing access to time-critical diagnostics in the acute and post-acute care phase.
“The partnership between Hyperfine and Viz.ai will help us integrate two breakthrough technologies that already enable us to better assess patients in a time-critical fashion and make timely decisions that will ultimately save more lives and improve outcomes,” said Shahid M. Nimjee, MD, PhD, Associate Professor of Neurosurgery, Surgical Director of the Comprehensive Stroke Center, The Ohio State University Medical Center. “By combining these two proven technologies, we hope to further expedite care, when every second matters and transportation presents additional risk.”
“Partnering with Hyperfine to enhance the clinical workflow and expedite the clinical team’s access to imaging has the potential to result in better patient outcomes where time is critical in the ER and ICU,” said Jayme Strauss, chief clinical officer at Viz.ai. “With this partnership, we will be able to combine Viz’s intelligent care coordination platform and leading image viewer with the Hyperfine Swoop Portable MR Imaging System™.”
“This new partnership between Viz.ai and Hyperfine has the potential to enable healthcare providers to reduce neuroimaging wait times, streamline their clinical workflow coordination, and improve patient care from door to discharge,” says Scott Huennekens, executive chairperson of the board of Hyperfine.
May 27, 2026 
